Core Viewpoint - China Nuclear Industry's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received approval for clinical trial application of its self-developed 2.2 class improved new drug, "Injectable Boron [10B] Falun" (BNCT boron drug), marking a significant advancement in the field of tumor treatment [1] Group 1 - The drug targets head and neck tumors that are resistant to radiotherapy and chemotherapy, showing significant clinical advantages, including a short treatment course of only 1-2 sessions and low toxicity [1] - This approval signifies a breakthrough in the collaborative research and development of BNCT drug-device integration, entering a new phase of clinical transformation [1] - The development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precise tumor treatment and contributing a "Chinese solution" to global cancer treatment [1]

Core Insights - China Biotechnology Services (08037) announced significant progress for its flagship project, Pengbo (Hainan) Boron Neutron Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone, with the NeuCure neutron irradiation system achieving its first beam output on November 20, 2025 [1] - The NeuCure system is the only boron neutron therapy system globally that has received formal medical device registration and can be directly applied in routine clinical treatment, not just in clinical trials [1] - Clinical treatment services are expected to officially commence in the first quarter of 2026, supported by favorable policies from the Boao Lecheng zone [1] Project Milestones - The successful beam output confirms that the core components of the system meet design specifications, marking a transition from equipment installation to beam debugging [1] - This milestone lays a solid foundation for subsequent key tasks, including precise neutron dose rate control, beam physics validation, and biological effect assessment [1] - The project aims to provide safe and precise boron neutron therapy services for cancer patients, ensuring high standards in clinical treatment progression [1]